Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12733909 | 0.83 | SMN1; SMN2 (0.47) | ALDH1A1MAPK1SMN1; SMN2POLBL3MBTL1 | |
| SCHEMBL20457102 | 0.83 | LMNA (0.37) | ALDH1A1MAPK1SMN1; SMN2POLBLMNA | |
| SCHEMBL19833124 | 0.75 | ALDH1A1 (0.31) | ALDH1A1MAPK1SMN1; SMN2POLBLMNA | |
| SCHEMBL2091242 | 0.72 | LMNA (0.47) | ALDH1A1MAPK1SMN1; SMN2POLBLMNA | |
| SCHEMBL29892233 | 0.72 | ALDH1A1 (0.43) | ALDH1A1MAPK1SMN1; SMN2POLBLMNA | |
| SCHEMBL5843250 | 0.72 | ALDH1A1 (0.43) | ALDH1A1MAPK1SMN1; SMN2POLBLMNA | |
| SCHEMBL30124712 | 0.70 | POLB (0.45) | ALDH1A1MAPK1SMN1; SMN2POLBLMNA | |
| SCHEMBL1886976 | 0.70 | POLB (0.45) | ALDH1A1MAPK1SMN1; SMN2POLBLMNA | |
| SCHEMBL20457088 | 0.70 | LMNA (0.37) | ALDH1A1MAPK1SMN1; SMN2POLBLMNA | |
| SCHEMBL78162 | 0.69 | L3MBTL1 (0.39) | ALDH1A1SMN1; SMN2POLBL3MBTL1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180028660-A1 | DRUG COMBINATIONS COMPRISING A DGAT INHIBITOR AND A PPAR-AGONIST | JANSSEN PHARMACEUTICA NV (BE) | 2018-02-01 | — | — | US | disclosed |
| US-20180028660-A1 | DRUG COMBINATIONS COMPRISING A DGAT INHIBITOR AND A PPAR-AGONIST | JANSSEN PHARMACEUTICA NV (BE) | 2018-02-01 | — | — | US | disclosed |
| US-9724418-B2 | Drug combinations comprising a DGAT inhibitor and a PPAR-agonist | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-08 | — | — | US | disclosed |
| US-9724418-B2 | Drug combinations comprising a DGAT inhibitor and a PPAR-agonist | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-08 | — | — | US | disclosed |
| US-20160081997-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-24 | — | — | US | disclosed |
| US-9227935-B2 | Piperidine/piperazine derivatives | JANSSEN PHARMACEUTICAL N.V. (BE) | 2016-01-05 | — | — | US | disclosed |
| US-20150320741-A1 | DRUG COMBINATIONS COMPRISING A DGAT INHIBITOR AND A PPAR-AGONIST | JANSSEN PHARMACEUTICA NV (BE) | 2015-11-12 | — | — | US | disclosed |
| US-9107946-B2 | Drug combinations comprising a DGAT inhibitor and a PPAR-agonist | JANSSEN PHARMACEUTICA NV (BE) | 2015-08-18 | — | — | US | disclosed |
| US-20150087629-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2015-03-26 | — | — | US | disclosed |
| US-8946228-B2 | Piperidine/piperazine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2015-02-03 | — | — | US | disclosed |
| US-20110112111-A1 | DRUG COMBINATIONS COMPRISING A DGAT INHIBITOR AND A PPAR-AGONIST | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-12 | — | — | US | disclosed |
| US-20100210618-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-08-19 | — | — | US | disclosed |
| US-20080312435-A1 | Imine Compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-20080312435-A1 | Imine Compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312435-A1 | Imine Compound | CNR1, CNR2, HRH4 | ALDH1A1 2674/4885MAPK1 2068/4885SMN1; SMN2 1844/4885 |
| US-20150320741-A1 | DRUG COMBINATIONS COMPRISING A DGAT INHIBITOR AND A PPAR-AGONIST | PPARG, PPARA, DGAT1 | ALDH1A1 585/4885MAPK1 2613/4885SMN1; SMN2 4874/4885 |
| US-20180028660-A1 | DRUG COMBINATIONS COMPRISING A DGAT INHIBITOR AND A PPAR-AGONIST | PPARG, PPARA, DGAT1 | ALDH1A1 585/4885MAPK1 2613/4885SMN1; SMN2 4874/4885 |
| US-20100210618-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | DGAT1, DGAT2, NAT1 | ALDH1A1 150/4885MAPK1 886/4885SMN1; SMN2 4358/4885 |
| US-20150087629-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | DGAT1, NAT1, SOAT1 | ALDH1A1 189/4885MAPK1 698/4885SMN1; SMN2 4330/4885 |
| US-20110112111-A1 | DRUG COMBINATIONS COMPRISING A DGAT INHIBITOR AND A PPAR-AGONIST | PPARG, PPARA, DGAT1 | ALDH1A1 585/4885MAPK1 2613/4885SMN1; SMN2 4874/4885 |
| US-20160081997-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | DGAT1, DGAT2, SOAT1 | ALDH1A1 231/4885MAPK1 718/4885SMN1; SMN2 4337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.